For the majority of melanoma patients, much more effective therapies are available today than a few years ago. This also applies to adjuvant melanoma treatment. Many new therapeutic approaches have been established and are being successively investigated in larger and smaller studies. This includes the interim analysis presented at this year’s ADF Annual Meeting.